Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive treatment

Gisondi, Paolo; Zaza, Gianluigi; Giglio, Micol Del; Rossi, M.; Iacono, Valentina; Girolomoni, Giampiero

doi:10.1016/j.jaad.2020.04.085

Cited by 51 publications

(52 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[1][2][3] Recently, few papers describe chilblain-like lesions (CLL) as a possible skin clue of COVID-19 among young patients and children, mostly in the absence of systemic symptoms and with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) swab negativity. [4][5][6][7][8] This observation is consistent with the atypical outbreak of CLL reported in high endemic COVID-19 Italian regions among paediatric and dermatological networks. 6 We hereby report a case of an adolescent boy with a reverse transcriptase (RT)-PCR-confirmed COVID-19 who developed long-lasting CLL.…”

Section: Histologic Features Of Longlasting Chilblain-like Lesions Insupporting

confidence: 87%

“…Our case reflects the prototype reported in the literature: an adolescent in good health with occasional history of systemic symptoms preceding cutaneous lesions. [4][5][6][7][8] Interestingly, we observed in our patient long-lasting skin lesions several weeks after the first showings of the symptoms, concurrently with the positivity of the nasopharyngeal swab.…”

Section: Histologic Features Of Longlasting Chilblain-like Lesions Insupporting

confidence: 52%

See 1 more Smart Citation

Histologic features of long‐lasting chilblain‐like lesions in a paediatric COVID‐19 patient

Locatelli

Test

Vezzoli

et al. 2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

Section: Histologic Features Of Longlasting Chilblain-like Lesions Insupporting

confidence: 87%

Section: Histologic Features Of Longlasting Chilblain-like Lesions Insupporting

confidence: 52%

Histologic features of long‐lasting chilblain‐like lesions in a paediatric COVID‐19 patient

Locatelli

Test

Vezzoli

et al. 2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…This happened despite recommendations of the Italian Society of Dermatology -SIDeMaST (10). Indeed, no increased risk of hospitalization or death from COVID-19 was recently reported in psoriatic patients treated with biological therapies (21)(22)(23)(24). On the other hand, worsening of the disease has been also experienced by patients who continued the treatment and this was due mainly to the psychological distress deriving by the lockdown (25) as pointed out by the correlation found between HADS, BRS and PSS alterations and the worsening of psoriasis, confirming the wellknown relationship between psychological distress and the cutaneous immune response (26,27).…”

Section: Discussionmentioning

confidence: 99%

The impact of COVID-19 pandemic in a cohort of Italian psoriatic patients treated with biological therapies

Pirrò

Caldarola

Chiricozzi

et al. 2020

Journal of Dermatological Treatment

View full text Add to dashboard Cite

Background: The beginning of 2020 has been marked by COVID-19 pandemic, with a strong impact on several national health systems worldwide. Objective: To describe the impact of COVID-19 pandemic in a cohort of Italian psoriatic patients treated with biologics. Methods: A telephone survey was conducted in May 4-10 2020 about the Italian lockdown period (March 9-May 3 2020) in a cohort of psoriatic patients treated with biologics, asking about any exposure to COVID-19, disease status, continuation of therapy, work activity and psychological status through Hospital Anxiety and Depression Scale (HADS), Perceived Stress Scale (PSS) and Brief Resilience Scale (BRS). Results: 226 patients were interviewed, with no COVID-19 positive cases. Sixty-three of 226 (27.9%) described worsening of the disease with a correlation to drug withdrawal [43/226 (19%)]. Correlation was also found between the worsening of psoriasis and HADS anxiety, HADS depression, BRS and PSS abnormal scores considered both as categorical and continuous variables. No correlation was found between worsening of psoriasis and work activity. Conclusion: Uncertainty about whether biologics could increase the risk of SARS-CoV-2 infection led to drug withdrawal with subsequent worsening of psoriasis. Moreover, psychological status also had a direct influence on the clinical course of the disease.

show abstract

“…8,9 To date, there is neither an agreement nor a study sustaining the impact of continuing or stopping biologics in psoriatic patients during the COVID-19 pandemic. [10][11][12][13][14][15][16] Furthermore, data on the epidemiology of COVID-19 disease in patients treated with biological drugs are very scarce. 8 A C…”

mentioning

confidence: 99%

Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study

Talamonti

Galluzzo

Chiricozzi

et al. 2021

Expert Opinion on Biological Therapy

Self Cite

View full text Add to dashboard Cite

Background The susceptibility of patients with chronic plaque psoriasis and the risks or benefits related to the use of biological therapies for COVID-19 are unknown. Few data about prevalence, clinical course and outcomes of COVID-19 among psoriatic patients were reported. The aims of this study were 1) to assess the prevalence and severity of COVID-19 in psoriatic patients treated with biologic agents during the first phase of the emergency (22 February to 22 April 2020) in Italy, and 2) to report the clinical outcomes of patients who have been exposed to individuals with confirmed SARS-CoV-2 infection. Methods Patients with moderate-to-severe chronic plaque psoriasis, aged ≥18 years and undergoing treatment with biologic agents as of 22 February 2020, were eligible to be included in PSO-BIO-COVID study. Demographic and clinical characteristics of patients using any biologic for psoriasis treatment between 22 February and 22 April 2020 were registered. For all confirmed or suspected cases of COVID-19, data about concomitant disease, ongoing therapies, and comorbidities were also reported. Results A total of 12,807 psoriatic patients were included in the PSO-BIO-COVID study. In this cohort twenty-six patients (0.2%) had a swab confirmation of SARS-CoV-2 infection. Eleven patients required hospitalization and two died. 125 of 12807 patients (1.0%) with exposure to a patient with COVID-19 under quarantine or active health surveillance, were reported. Conclusion The incidence of COVID-19 observed in our cohort of psoriatic patients (0.2%) is similar to that seen in the general population (0.31%) in Italy. However, the course of the disease was mild in most patients. Biological therapies may likely lessen "cytokine storm" of COVID-19, which sometimes lead to multiple organ failure, ARDS, and death.

show abstract

Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive treatment

Cited by 51 publications

References 1 publication

Histologic features of long‐lasting chilblain‐like lesions in a paediatric COVID‐19 patient

Histologic features of long‐lasting chilblain‐like lesions in a paediatric COVID‐19 patient

The impact of COVID-19 pandemic in a cohort of Italian psoriatic patients treated with biological therapies

Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study

Contact Info

Product

Resources

About